CD8A and neoplasm: Effective therapeutic cancer vaccination requires the optimization of tumor antigen presentation by antigen-presenting cells (APCs) to induce strong antigen-specific T cell responses, especially CD8+ cytolytic T lymphocytes (CTLs) with a sufficiently broad repertoire and immunologic memory [1].